AIM ImmunoTech Inc. — Form 8-K
Filed September 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
AIM ImmunoTech is exchanging a portion of a $3.301M promissory note issued to Streeterville Capital, LLC (dated February 16, 2024) for an unspecified number of common shares. The exact dollar amount of the partitioned note and share count are blank in the template filing. Shares will be issued free-trading under Rule 144, with holding period tacking back to February 2024. The Original Note's outstanding balance will be reduced by the partitioned amount; remaining obligations under the original note continue.
Why this rating
Debt-to-equity conversion of ~3.3M (52% of company market cap) is meaningful restructuring; however, lacks specificity on conversion terms, share dilution, and exact amount converted. Neutral because refinancing/restructuring is typical for distressed small caps; direction depends on undisclosed valuation and dilution.
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.